Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma
William W. Busse, Pierluigi Paggiaro, Xavier Muñoz, Thomas B. Casale, Mario Castro, Giorgio Walter Canonica, John Aubrey Douglass, Yuji Tohda, Nadia Daizadeh, Benjamin Ortiz, Nami Pandit‐Abid
Abstract
<b>Dupilumab treatment <i>versus</i> placebo improved exacerbation rate and lung function outcomes in patients with uncontrolled moderate-to-severe asthma and high type 2 biomarkers at baseline, regardless of baseline characteristics in the phase 3 QUEST study</b>https://bit.ly/3yR7MlD
Topics & Concepts
DupilumabMedicineExacerbationPlaceboAsthmaLung functionBaseline (sea)Internal medicineLungPathologyAlternative medicineOceanographyGeologyAsthma and respiratory diseasesIL-33, ST2, and ILC PathwaysEosinophilic Esophagitis